{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T04:42:10Z","timestamp":1789965730921,"version":"4.0.1"},"reference-count":29,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2013,1,30]],"date-time":"2013-01-30T00:00:00Z","timestamp":1359504000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2013,3]]},"abstract":"\n Cisplatin (\n CDDP<\/jats:styled-content>\n ) has been a key drug for chemotherapy in patients with head and neck squamous cell carcinoma. Nephrotoxicity is one of its adverse reactions that are dose limiting. To increase its antitumor effects and reduce such toxicity problems, polymeric micelles carrying\n CDDP<\/jats:styled-content>\n (\n NC<\/jats:styled-content>\n \u20106004) have been developed. The present study was designed to evaluate the efficacy and safety of\n NC<\/jats:styled-content>\n \u20106004 for oral squamous cell carcinoma.\n In vitro<\/jats:italic>\n antitumor activity was assayed in four oral squamous cell carcinoma cell lines. To investigate the antitumor and nephrotoxic effects of\n NC<\/jats:styled-content>\n \u20106004, nude mice bearing\n OSC<\/jats:styled-content>\n \u201019 were administered\n NC<\/jats:styled-content>\n \u20106004 or\n CDDP<\/jats:styled-content>\n . The\n in vitro<\/jats:italic>\n growth\u2010inhibitory effect of\n NC<\/jats:styled-content>\n \u20106004 was significantly less than that of\n CDDP<\/jats:styled-content>\n . However, both\n NC<\/jats:styled-content>\n \u20106004 and\n CDDP<\/jats:styled-content>\n showed equivalent antitumor effects\n in vivo<\/jats:italic>\n . Mice with\n CDDP<\/jats:styled-content>\n developed renal cell apoptosis; however, those injected with\n NC<\/jats:styled-content>\n \u20106004 were almost free of renal cell injury. Moreover, in an orthotopic tongue cancer model using\n OSC<\/jats:styled-content>\n \u201019,\n NC<\/jats:styled-content>\n \u20106004 reduced the rate of sentinel lymph node metastasis to lower than that with\n CDDP<\/jats:styled-content>\n . In conclusion, considering the potential advantages in terms of noticeable antitumor activity, lymphatic drug delivery and reduced nephrotoxicity,\n NC<\/jats:styled-content>\n \u20106004 represents a significant structural improvement in the development of a platinum complex.\n <\/jats:p>","DOI":"10.1111\/cas.12079","type":"journal-article","created":{"date-parts":[[2012,12,6]],"date-time":"2012-12-06T13:56:08Z","timestamp":1354802168000},"page":"369-374","source":"Crossref","is-referenced-by-count":105,"title":["Tumor\u2010targeted chemotherapy with the nanopolymer\u2010based drug\n NC<\/scp>\n \u20106004 for oral squamous cell carcinoma"],"prefix":"10.1111","volume":"104","author":[{"given":"Kazuhira","family":"Endo","sequence":"first","affiliation":[{"name":"Division of Otolaryngology Graduate School of Medical Science Kanazawa University Ishikawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayoshi","family":"Ueno","sequence":"additional","affiliation":[{"name":"Division of Otolaryngology Graduate School of Medical Science Kanazawa University Ishikawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Kondo","sequence":"additional","affiliation":[{"name":"Division of Otolaryngology Graduate School of Medical Science Kanazawa University Ishikawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Wakisaka","sequence":"additional","affiliation":[{"name":"Division of Otolaryngology Graduate School of Medical Science Kanazawa University Ishikawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeyuki","family":"Murono","sequence":"additional","affiliation":[{"name":"Division of Otolaryngology Graduate School of Medical Science Kanazawa University Ishikawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Ito","sequence":"additional","affiliation":[{"name":"Division of Otolaryngology Graduate School of Medical Science Kanazawa University Ishikawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Kataoka","sequence":"additional","affiliation":[{"name":"Department of Materials Engineering Graduate School of Engineering The University of Tokyo Tokyo Japan"},{"name":"Division of Clinical Biotechnology Center for Disease Biology and Integrative Medicine Graduate School of Medicine The University of Tokyo Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuki","family":"Kato","sequence":"additional","affiliation":[{"name":"Research Division NanoCarrier Co., Ltd Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomokazu","family":"Yoshizaki","sequence":"additional","affiliation":[{"name":"Division of Otolaryngology Graduate School of Medical Science Kanazawa University Ishikawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,1,30]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2982"},{"key":"e_1_2_7_3_1","first-page":"559","article-title":"Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review)","volume":"11","author":"Boulikas T","year":"2004","journal-title":"Oncol Rep"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00686277"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/000348940711601007"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2614"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1632"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2006.05.006"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(00)00124-1"},{"key":"e_1_2_7_10_1","first-page":"8977","article-title":"Novel cisplatin\u2010incorporated polymeric micelles can eradicate solid tumors in mice","volume":"63","author":"Nishiyama N","year":"2003","journal-title":"Cancer Res"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602772"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-3659(01)00309-1"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/1758-3284-1-32"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00928.x"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1020329411957"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2012.01.008"},{"key":"e_1_2_7_17_1","first-page":"1693","article-title":"Characterization and anticancer activity of the micelle\u2010forming polymeric anticancer drug adriamycin\u2010conjugated poly(ethylene glycol)\u2010poly(aspartic acid) block copolymer","volume":"50","author":"Yokoyama M","year":"1990","journal-title":"Cancer Res"},{"key":"e_1_2_7_18_1","first-page":"3229","article-title":"Toxicity and antitumor activity against solid tumors of micelle\u2010forming polymeric anticancer drug and its extremely long circulation in blood","volume":"51","author":"Yokoyama M","year":"1991","journal-title":"Cancer Res"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyn116"},{"key":"e_1_2_7_20_1","first-page":"1663","article-title":"Cisplatin and platinum drugs at the molecular level. (Review)","volume":"10","author":"Boulikas T","year":"2003","journal-title":"Oncol Rep"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO;2-0"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(86)80111-1"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000042803.28024.92"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.6"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19930115)71:2<452::AID-CNCR2820710228>3.0.CO;2-B"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlg.0000161338.54515.b1"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0215(20010120)95:1<44::AID-IJC1008>3.0.CO;2-M"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2012.02.003"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.1992.01420040034005"},{"key":"e_1_2_7_30_1","first-page":"577","article-title":"The diffusion of dextrans of different molecular sizes to lymph and urine","volume":"38","author":"Grotte G","year":"1951","journal-title":"J Lab Clin Med"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcas.12079","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.12079","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:29:43Z","timestamp":1700612983000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cas.12079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,30]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["10.1111\/cas.12079"],"URL":"https:\/\/doi.org\/10.1111\/cas.12079","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,30]]}}}